Osteoarthritis Epidemiology Analysis and Forecast, 2021-2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Osteoarthritis Epidemiology Market Overview

Osteoarthritis (OA) market size was 18,820,737 cases in 2021 cases across 7MM. The market is expected to grow at an AGR of more than 1% during the forecast period.

The Osteoarthritis epidemiology market research report provides an overview of the risk factors, comorbidities, and global and historical trends for hand OA, knee OA, and hip OA in the seven major markets or 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases, total prevalent cases, and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA segmented by age (18 years and older) and sex in these markets.

Osteoarthritis Epidemiology Analysis

For more insights on the Osteoarthritis market forecast, download a free report sample

Osteoarthritis Market Segments

The key segments in the Osteoarthritis market are hand OA, knee OA, and hip OA.

Hand Osteoarthritis

IIn the 7MM, epidemiologists forecast that the total prevalent cases (radiographic) of hand OA will increase by 2031. Among the 7 major market, the US had the highest number of total prevalent cases (radiographic) of hand OA in 2021. The UK, on the other hand, had the lowest number of total prevalent cases (radiographic) of hand OA in 2016.

The prevalence of hand OA increases with advancing age but decreases for the oldest age groups. In the 7MM, the age group 18–29 years had the lowest number of diagnosed prevalent cases (symptomatic), whereas the highest number of diagnosed prevalent cases (symptomatic) was in the age group 60–69 years. The differences in the number of diagnosed prevalent cases (symptomatic) of hand OA across the various age groups and markets may be attributed to differences in the actual age-specific diagnosed prevalence (symptomatic) of hand OA, combined with differences in the population demographics in these markets.

Knee Osteoarthritis

In the 7MM, epidemiologists forecast that the total prevalent cases (symptomatic) of knee OA will increase by 2031. The US had the highest number of total prevalent cases (symptomatic) of knee OA in 2021.

The prevalence of knee OA increases with advancing age but decreases for the oldest age groups. In the 7MM, the age group 18–29 years had the lowest number of diagnosed prevalent cases (symptomatic), whereas the highest number of diagnosed prevalent cases (symptomatic) was in the age group 60–69 years. The differences in the number of diagnosed prevalent cases (symptomatic) of knee OA across the various age groups and markets may be attributed to differences in the actual age-specific diagnosed prevalence (symptomatic) of knee OA, combined with differences in the population demographics in these markets.

Hip Osteoarthritis

In the 7MM, epidemiologists forecast that the total prevalent cases (radiographic) of hip OA will increase by 2031. The US had the highest number of total prevalent cases (radiographic) of hip OA in 2021. The prevalence of hip OA increases with advancing age but decreases for the oldest age groups. In the 7MM, the age group 18–29 years had the lowest number of diagnosed prevalent cases (symptomatic), whereas the highest number of diagnosed prevalent cases (symptomatic) was in the age group 70–79 years. The differences in the number of diagnosed prevalent cases (symptomatic) of hip OA across the various age groups and markets may be attributed to differences in the actual age-specific diagnosed prevalence (symptomatic) of hip OA, combined with differences in the population demographics in these markets.

Osteoarthritis Market Report Overview

Market Size 2021 18,820,737 cases
AGR % (2021-2031) >1%
Key Segments Hand OA, Knee OA, and Hip OA

 

Osteoarthritis Epidemiology Market Segments Outlook, (2021-2031)

  • Hand OA
  • Knee OA
  • Hip OA

Scope

  • This report provides an overview of the risk factors, comorbidities, and the global and historical trends for osteoarthritis (OA) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report provides a 10-year epidemiological forecast for the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA segmented by age (18 years and older) and sex in these markets.
  • The diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA are further segmented by severity using Kellgren-Lawrence (KL) grading into mild (KL = 2), and moderate to severe (KL = 3 to 4). The model accompanying this report also provides the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA and the listed segments.
  • The osteoarthritis epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The osteoarthritis epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global osteoarthritis market.
  • Quantify patient populations in the global osteoarthritis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for osteoarthritis therapeutics in each of the markets covered.
  • Enable to understand the magnitude of hand, knee, and hip osteoarthritis and the severity.

Table of Contents

| About GlobalData

1 Osteoarthritis: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 7MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Forecast Assumptions and Methods: Total Prevalent Cases (Radiographic)

2.4.4 Forecast Assumptions and Methods: Total Prevalent Cases (Symptomatic)

2.4.5 Forecast Assumptions and Methods: Diagnosed Prevalent Cases (Symptomatic)

2.4.6 Forecast Assumptions and Methods: Diagnosed Prevalent Cases (Symptomatic) by Severity

2.5 Epidemiological Forecast for OA (2021–31)

2.5.1 Total Prevalent Cases (Radiographic) of Hand OA

2.5.2 Total Prevalent Cases (Symptomatic) of Hand OA

2.5.3 Diagnosed Prevalent Cases (Symptomatic) of Hand OA

2.5.4 Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Hand OA

2.5.5 Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Hand OA

2.5.6 Diagnosed Prevalent Cases (Symptomatic) of Hand OA by Severity

2.5.7 Total Prevalent Cases (Radiographic) of Knee OA

2.5.8 Total Prevalent Cases (Symptomatic) of Knee OA

2.5.9 Diagnosed Prevalent Cases (Symptomatic) of Knee OA

2.5.10 Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Knee OA

2.5.11 Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Knee OA

2.5.12 Diagnosed Prevalent Cases (Symptomatic) of Knee OA by Severity

2.5.13 Total Prevalent Cases (Radiographic) of Hip OA

2.5.14 Total Prevalent Cases (Symptomatic) of Hip OA

2.5.15 Diagnosed Prevalent Cases (Symptomatic) of Hip OA

2.5.16 Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Hip OA

2.5.17 Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Hip OA

2.5.18 Diagnosed Prevalent Cases (Symptomatic) of Hip OA by Severity

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Summary of Updated Data Types

Table 2: Risk Factors and Comorbid Conditions Associated with OA

Table 3: Severity Scoring System for Classifying the Hand, Knee, and Hip OA Using the KL Grading Scale.

Figures

Figure 1: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, N, Ages ≥18 Years, 2021 and 2031

Figure 2: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, N, Ages ≥18 Years, 2021 and 2031

Figure 3: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, N, Ages ≥18 Years, 2021 and 2031

Figure 4: 7MM, Diagnosed Prevalence (Symptomatic) (%), Hand OA, Both Sexes, Ages ≥18 Years, 2021

Figure 5: 7MM, Diagnosed Prevalence (Symptomatic) (%), Knee OA, Both Sexes, Ages ≥18 Years, 2021

Figure 6: 7MM, Diagnosed Prevalence (Symptomatic) (%), Hip OA, Both Sexes, Ages ≥18 Years, 2021

Figure 7: 7MM, Sources Used to Forecast the Total Prevalent Cases (Radiographic), Hand OA

Figure 8: 7MM, Sources Used to Forecast the Total Prevalent Cases (Radiographic), Knee OA

Figure 9: 7MM, Sources Used to Forecast the Total Prevalent Cases (Radiographic), Hip OA

Figure 10: 7MM, Sources Used to Forecast the Total Prevalent Cases (Symptomatic), Hand OA

Figure 11: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases (Symptomatic), Knee OA

Figure 12: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases (Symptomatic), Hip OA

Figure 13: 7MM, Total Prevalent Cases (Radiographic) of Hand OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 14: 7MM, Total Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 15: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 16: 7MM, Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 17: 7MM, Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 18: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hand OA by Severity, Both Sexes, Ages ≥18 Years, N, 2021

Figure 19: 7MM, Total Prevalent Cases (Radiographic) of Knee OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 20: 7MM, Total Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 21: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 22: 7MM, Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 23: 7MM, Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 24: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Knee OA by Severity, Both Sexes, Ages ≥18 Years, N, 2021

Figure 25: 7MM, Total Prevalent Cases (Radiographic) of Hip OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 26: 7MM, Total Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 27: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 28: 7MM, Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 29: 7MM, Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, Ages ≥18 Years, N, 2021

Figure 30: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hip OA by Severity, Both Sexes, Ages ≥18 Years, N, 2021

Frequently asked questions

Osteoarthritis Epidemiology Analysis and Forecast, 2021-2031 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Osteoarthritis Epidemiology Analysis and Forecast, 2021-2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Osteoarthritis Epidemiology Analysis and Forecast, 2021-2031 in real time.

  • Access a live Osteoarthritis Epidemiology Analysis and Forecast, 2021-2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.